| Quick-Release Bromocriptine for Treatment of Type 2 Diabetes. | |
| | |
MedLine Citation:
|
PMID: 21696353 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Quick-release bromocriptine (bromocriptine-QR) (Cycloset) was approved in 2009 for treatment of type 2 diabetes. The exact anti-diabetic mechanism of action of bromocriptine-QR has not been elucidated, but the drug may help resetting the circadian dopamine signal. Randomized placebo-controlled trials showed that the mean reduction in hemoglobin A1c (HbA1c) levels by bromocriptine-QR was 0.0-0.2% when compared to baseline and 0.4-0.5% when compared with placebo after 24 weeks of therapy. Withdrawal rates due to adverse effects in patients receiving bromocriptine-QR and placebo were 24% and 11%, respectively. The most common adverse effect of bromocriptine-QR was nausea reported by 32% of patients compared with 7% of patients randomized to placebo. The advantages of bromocriptine-QR were minimal risk of hypoglycemia, neutral effect on weight, and reassuring cardiovascular safety over 1 year of use. However, the drug had multiple drawbacks including modest efficacy, high rates of nausea, lack of long-term efficacy and safety data, and considerable cost. Bromocriptine-QR may be used in patients with type 2 diabetes with mild hyperglycemia (HbA1c close to 7.5%) either as adjunctive treatment to metformin and sulfonylurea (SU) or as monotherapy in patients who are intolerant to both agents. |
| | |
Authors:
|
Nasser Mikhail |
Related Documents
:
|
16430493 - Characterization of obesity in japanese monkeys (macaca fuscata) in a pedigreed colony. 20389103 - Retinol-binding protein 4 levels in obese children and adolescents with glucose intoler... 1425433 - Diminished insulinotropic effects of gastrin-releasing peptide in pregnant sheep are re... |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-6-22 |
Journal Detail:
|
Title: Current drug delivery Volume: - ISSN: 1875-5704 ISO Abbreviation: - Publication Date: 2011 Jun |
Date Detail:
|
Created Date: 2011-6-23 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101208455 Medline TA: Curr Drug Deliv Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Endocrinology Division, Department of Medicine, Olive-View-UCLA Medical Center, 14445 Olive, View Drive, Sylmar, CA 91342, USA. nmikhail@dhs.lacounty.gov. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: In vitro and In vivo Characterization of Novel Biomaterial for Transdermal Application.
Next Document: Floating Drug Delivery Systems for Prolonging Gastric Residence Time: A Review.